piperaquine pbpk model (Simcyp)
86
Structured Review
Simcyp
piperaquine pbpk model
Piperaquine Pbpk Model, supplied by Simcyp, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pbpk+models/model+pbpk+piperaquine/pmc13163144-22-1-10
Average 86 stars, based on 1 article reviews
Piperaquine Pbpk Model, supplied by Simcyp, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/pbpk+models/model+pbpk+piperaquine/pmc13163144-22-1-10
Average 86 stars, based on 1 article reviews
piperaquine pbpk model - by Bioz Stars,
2026-10
86/100 stars
Images
1) Product Images from "Physiologically‐Based Pharmacokinetic Modeling to Investigate Piperaquine Exposure in Pregnant Women Using an Individualized Profile Approach"
Article Title: Physiologically‐Based Pharmacokinetic Modeling to Investigate Piperaquine Exposure in Pregnant Women Using an Individualized Profile Approach
Journal: Clinical and Translational Science
doi: 10.1111/cts.70589
Figure Legend Snippet: Overview of the workflow for physiologically‐based pharmacokinetic modeling of piperaquine for a pregnant population using an individualized profile (‘virtual twin’) approach.
Techniques Used:
Figure Legend Snippet: Individual piperaquine normalized AUC ratios ( R AUC / Dose ) for the first dose (blue solid line) and last dose (blue dotted line) in (a) Sudanese pregnant women, second trimester; (b) Sudanese pregnant women, third trimester; (c) Thai pregnant women, second trimester; (d) Thai pregnant women, third trimester. Internal gray line: R AUC = 0 , middle gray line: R AUC = 1 , and external gray line: R AUC = 2 . ID, identification number for the women included in the clinical trials. ID = patient identification number.
Techniques Used: Clinical Proteomics
Figure Legend Snippet: Mean plasma concentration–time plots for piperaquine in plasma in representative individualized profiles compared to observed data for (a) a Sudanese pregnant woman (second trimester, patient ID7), and (b) a Thai pregnant woman (second trimester, patient ID6). The shaded area is 95% prediction interval.
Techniques Used: Clinical Proteomics, Concentration Assay
Figure Legend Snippet: Predicted vs. observed piperaquine clearance up to Day 7 in (a) Sudanese pregnant women, and (b) Thai pregnant women. The central line is the median, the box represents the interquartile range, the cross is the mean, and the whiskers are the lowest and highest values.
Techniques Used:
Figure Legend Snippet: Piperaquine concentrations on Day 7 for (a) individual predicted vs. observed plasma concentrations and predictive performance assessed by (b) prediction error (PE), and (c) relative difference (RD). The central line is the median, the box represents the interquartile range, the cross is the mean, and the whiskers are the lowest and highest values. All the predicted concentrations were normalized by the actual mg/kg dose administered to the patient. T2 = second trimester; T3 = third trimester.
Techniques Used: Clinical Proteomics
Related Articles
Drug discovery:Article Title: Exploring the Impact of Developmental Clearance Saturation on Propylene Glycol Exposure in Adults and Term Neonates Using Physiologically Based Pharmacokinetic Modeling. Article Snippet: .. See the T erm s and C onditions (https://onlinelibrary.w iley.com /term s-and-conditions) on W iley O nline L ibrary for rules of use; O A articles are governed by the applicable C reative C om m ons L icense PG Physiologically Based Pharmacokinetic (PBPK) Model Development The Recombinant:Article Title: PBPK Modelling for Drugs Cleared by Non-CYP Enzymes: State-of-the-Art and Future Perspectives. Article Snippet: Physiologically-based pharmacokinetic (PBPK) modeling has become the established method for predicting human pharmacokinetics (PK) and drug-drug interactions (DDI).. The number of drugs cleared by non-CYP enzyme metabolism has increased steadily and to date, there is no consolidated overview of PBPK modeling for drugs cleared by non-CYP enzymes.. This review aims to describe the state-of-the-art PBPK modeling for drugs cleared via non-CYP enzymes, to identify successful strategies, to describe gaps and to provide suggestions to overcome them. In Vitro:Article Title: PBPK Modelling for Drugs Cleared by Non-CYP Enzymes: State-of-the-Art and Future Perspectives. Article Snippet: Physiologically-based pharmacokinetic (PBPK) modeling has become the established method for predicting human pharmacokinetics (PK) and drug-drug interactions (DDI).. The number of drugs cleared by non-CYP enzyme metabolism has increased steadily and to date, there is no consolidated overview of PBPK modeling for drugs cleared by non-CYP enzymes.. This review aims to describe the state-of-the-art PBPK modeling for drugs cleared via non-CYP enzymes, to identify successful strategies, to describe gaps and to provide suggestions to overcome them. Article Title: Building Confidence in Physiologically Based Pharmacokinetic Modeling of CYP3A Induction Mediated by Rifampin: An Industry Perspective. Article Snippet: .. Hence building confidence in PBPK modeling to predict DDIs and inform drug labeling of CYP3A substrates offers an alternative approach for drug development.5,13,14 This strategy was recently used successfully for vonoprazan, where instead of conducting a strong inducer clinical DDI study, PBPK simulations were used to inform drug labeling.15,16 other:Article Title: Physiologically Based Pharmacokinetic Modeling of Cannabidiol, Delta‐9‐Tetrahydrocannabinol, and Their Metabolites in Healthy Adults After Administration by Multiple Routes Article Snippet: PBPK models for these precipitants were applied from the Labeling:Article Title: Building Confidence in Physiologically Based Pharmacokinetic Modeling of CYP3A Induction Mediated by Rifampin: An Industry Perspective. Article Snippet: .. Hence building confidence in PBPK modeling to predict DDIs and inform drug labeling of CYP3A substrates offers an alternative approach for drug development.5,13,14 This strategy was recently used successfully for vonoprazan, where instead of conducting a strong inducer clinical DDI study, PBPK simulations were used to inform drug labeling.15,16 Software:Article Title: Building Confidence in Physiologically Based Pharmacokinetic Modeling of CYP3A Induction Mediated by Rifampin: An Industry Perspective. Article Snippet: .. Hence building confidence in PBPK modeling to predict DDIs and inform drug labeling of CYP3A substrates offers an alternative approach for drug development.5,13,14 This strategy was recently used successfully for vonoprazan, where instead of conducting a strong inducer clinical DDI study, PBPK simulations were used to inform drug labeling.15,16 In Vivo:Article Title: Building Confidence in Physiologically Based Pharmacokinetic Modeling of CYP3A Induction Mediated by Rifampin: An Industry Perspective. Article Snippet: .. Hence building confidence in PBPK modeling to predict DDIs and inform drug labeling of CYP3A substrates offers an alternative approach for drug development.5,13,14 This strategy was recently used successfully for vonoprazan, where instead of conducting a strong inducer clinical DDI study, PBPK simulations were used to inform drug labeling.15,16 Biomarker Discovery:Article Title: Building Confidence in Physiologically Based Pharmacokinetic Modeling of CYP3A Induction Mediated by Rifampin: An Industry Perspective. Article Snippet: .. Hence building confidence in PBPK modeling to predict DDIs and inform drug labeling of CYP3A substrates offers an alternative approach for drug development.5,13,14 This strategy was recently used successfully for vonoprazan, where instead of conducting a strong inducer clinical DDI study, PBPK simulations were used to inform drug labeling.15,16 |
